19:20 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Levels of miR-301a in serum-derived exosomes could help diagnose and predict progression in pancreatic cancer. In serum-derived exosomes from 50 patients, miR-301a levels were higher than in serum-derived exosomes from 12 healthy...
23:53 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Encephalitis Cell culture and mouse studies suggest inhibiting miR-301a could help treat Japanese encephalitis (JE). In a mouse hippocampal cell line infected with JE virus, knockdown of miR-301a decreased viral replication compared with normal...
07:00 , May 10, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) MicroRNA-301a (miR-301a) A study in mice suggests antagonizing miR-301a could help treat MS. In an experimental autoimmune encephalomyelitis (EAE) mouse model...
08:00 , Jan 6, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer MicroRNA-301a (miR-301a); NF-kB In vitro and mouse studies suggest that inhibiting miR-301a could help treat pancreatic cancer. In vitro, miR-301a activated expression of...